Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Dr.
Lebanon, NH 03756
Mark A. Cervinski, PhD
Telephone: 603 650 7114
Fax: 603 650 4845
Robert D. Nerenz, PhD
Telephone: 603 650 7114
Faculty and Research Interests
|Mark A. Cervinski, PhD, DABCC (CC)||General clinical chemistry, test utilization, based quality control (moving averages), toxicology|
|Robert D. Nerenz, PhD, DABCC (CC)||General clinical chemistry, endocrinology, molecular diagnostics, point of care testing|
|Jacqueline A. Hubbard, PhD, DABCC (CC)||General clinical chemistry, mass spectrometry, toxicology, therapeutic drug monitoring|
|Gregory J. Tsongalis, PhD, ABB (HCLD, CC)||Molecular diagnostics, cancer biology and global health|
|Joel A. Lefferts, PhD, ABB (HCLD)||Molecular diagnostics|
|Mary Beth P. Dinulos, MD, FACMG||Clinical genetics, test utilization|
Level(s) of training: Postdoctoral
Number of positions available per year: 1
Duration of program: 2 years
Approximate annual salary or stipend: Equal to PGY-1 Pathology Residency Salary
Source of funding: Departmental Funding
Current number of trainees: 2
Number of past graduates (over last 10 years): 4
Prerequisites: PhD, MD, or MD/PhD. PhD applicants must have earned their doctoral degree in chemistry, biology, molecular biology, pharmacology, toxicology, cell biology or other basic science degree from an accredited university. All applicants must meet the minimum 30 credit hours (or the equivalent) in undergraduate or graduate level chemistry or biochemistry courses in order to qualify for the ABCC Board examination.
Applicants must submit a letter of interest/intent, curriculum vitae and three letters of recommendation to the email@example.com email address. Candidates accepted for interviews must also be able to provide official transcripts that demonstrate completion of 30 credit hours in chemistry.
Application materials should be received by October 15th for consideration of positions beginning July 1st the following year. Electronic submission via email is encouraged.
The clinical chemistry fellowship program at Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine is designed to provide the fellow with a diverse exposure to clinical chemistry and laboratory medicine. The fellowship program includes exposure to a fully automated clinical chemistry laboratory that includes automated urine drug screening, immunology, endocrinology, and infectious disease serology in addition to general clinical chemistry. The fellow also receives training in the on-site special chemistry and immunology laboratory that currently houses two LC-MS/MS analyzers. The clinical chemistry service also has oversight of three stand-alone laboratories that provide general clinical chemistry, coagulation, hematology and urinalysis testing for three large physician practices in southern New Hampshire.
The training program will also expose the fellow to dynamic molecular pathology and translational research laboratories that enhance training by providing access to cutting edge molecular testing and research opportunities. The program at DHMC is also activity engaged in reference laboratory test utilization including the participation of a Medical Geneticist and Genetic Counsellor that contribute to the fellow’s training.
The program faculty are active within the Northeast AACC section and routinely attend the seven annually scheduled meetings in the Boston area. Fellows within the training program are strongly encouraged to also attend these educational and networking events.
Fellows are provided with a desk space in a common resident/fellow workroom for the duration of their training and are also provided with a competitive travel budget to be used to attend the AACC Annual meeting as well as other relevant meetings such as MSACL and ACLPS.
Completion of the two year fellowship training program will provide the fellow with in depth experiences in clinical laboratory medicine and will prepare the fellow with the necessary prerequisites to qualify for board eligibility from the American Board of Clinical Chemistry.